Basic Information
| RNALocate ID: | RLID:11002655 |
| RNA Symbol: | hsa-miR-338-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-338-3p |
| RNA ID: | miRBase:MIMAT0000763 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23382797 |
| Tissue/Cell Line: | Brain tissue |
| Method: | Microarray |
| Description: | We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA (Table S1). Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002084 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002085 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11002653 | Exosome | Serum | 18589210 |
| RLID:11002654 | Exosome | B cell line (Raji)|Primary dendritic cells | 21505438 |
| RLID:11002656 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002657 | Microvesicle | Serum | 24797360 |
| RLID-D:11000440 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001216 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-338-3p | Splenic marginal zone lymphoma | MNDR-E-MI-41250 |
| MNDR | hsa-miR-338-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-41251 |
| MNDR | hsa-miR-338-3p | Oral squamous cell carcinoma | MNDR-E-MI-41252 |
| MNDR | hsa-miR-338-3p | Large cell neuroendocrine cancer | MNDR-E-MI-41253 |
| MNDR | hsa-miR-338-3p | Follicular lymphoma | MNDR-E-MI-41254 |
| MNDR | hsa-miR-338-3p | Medulloblastoma | MNDR-E-MI-41255 |
| MNDR | hsa-miR-338-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-41256 |
| MNDR | hsa-miR-338-3p | Lymphoma | MNDR-E-MI-41257 |
| MNDR | hsa-miR-338-3p | Lymphoma non-hodgkin | MNDR-E-MI-41258 |
| MNDR | hsa-miR-338-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-41259 |
| MNDR | hsa-miR-338-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-41260 |
| MNDR | hsa-miR-338-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-41261 |
| MNDR | hsa-miR-338-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-41262 |
| MNDR | hsa-miR-338-3p | Breast cancer luminal | MNDR-E-MI-41263 |
| MNDR | hsa-miR-338-3p | Colorectal carcinoma | MNDR-E-MI-41264 |
| MNDR | hsa-miR-338-3p | Prostate cancer | MNDR-E-MI-41265 |
| MNDR | hsa-miR-338-3p | Hirschsprung disease | MNDR-E-MI-41266 |
| MNDR | hsa-miR-338-3p | Gastric cancer | MNDR-E-MI-41267 |
| MNDR | hsa-miR-338-3p | Alzheimer disease | MNDR-E-MI-41268 |
| MNDR | hsa-miR-338-3p | Intracranial aneurysm | MNDR-E-MI-41269 |
| MNDR | hsa-miR-338-3p | Bladder cancer | MNDR-E-MI-41270 |
| MNDR | hsa-miR-338-3p | Esophageal carcinoma | MNDR-E-MI-41271 |
| MNDR | hsa-miR-338-3p | Head and neck cancer | MNDR-E-MI-41272 |
| MNDR | hsa-miR-338-3p | Leukemia | MNDR-E-MI-41273 |
| MNDR | hsa-miR-338-3p | Huntington disease | MNDR-E-MI-41274 |
| MNDR | hsa-miR-338-3p | Chorea | MNDR-E-MI-41275 |
| MNDR | hsa-miR-338-3p | Cardiovascular disease | MNDR-E-MI-41276 |
| MNDR | hsa-miR-338-3p | Neurodegenerative diseases | MNDR-E-MI-41277 |
| MNDR | hsa-miR-338-3p | Moyamoya disease | MNDR-E-MI-41278 |
| MNDR | hsa-miR-338-3p | Lung cancer | MNDR-E-MI-41279 |
| MNDR | hsa-miR-338-3p | Parkinson disease | MNDR-E-MI-41280 |
| MNDR | hsa-miR-338-3p | Breast cancer | MNDR-E-MI-41281 |
| MNDR | hsa-miR-338-3p | Thyroid cancer | MNDR-E-MI-41282 |
| MNDR | hsa-miR-338-3p | Pancreatic cancer | MNDR-E-MI-41283 |
| MNDR | hsa-miR-338-3p | Rectum adenocarcinoma | MNDR-E-MI-41284 |
| MNDR | hsa-miR-338-3p | Nephroblastoma | MNDR-E-MI-41285 |
| MNDR | hsa-miR-338-3p | Colon cancer | MNDR-E-MI-41286 |
| MNDR | hsa-miR-338-3p | Colon adenocarcinoma | MNDR-E-MI-41287 |
| MNDR | hsa-miR-338-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-41288 |
| MNDR | hsa-miR-338-3p | Ovarian cancer | MNDR-E-MI-41289 |
| MNDR | hsa-miR-338-3p | Prostate adenocarcinoma | MNDR-E-MI-41290 |
| MNDR | hsa-miR-338-3p | Glioblastoma | MNDR-E-MI-41291 |
| MNDR | hsa-miR-338-3p | Glioma | MNDR-E-MI-41292 |
| MNDR | hsa-miR-338-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-41293 |
| MNDR | hsa-miR-338-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-41294 |
| MNDR | hsa-miR-338-3p | Temporal lobe epilepsy | MNDR-E-MI-41295 |
| MNDR | hsa-miR-338-3p | Osteosarcoma | MNDR-E-MI-41296 |
| MNDR | hsa-miR-338-3p | Meningioma | MNDR-E-MI-41297 |
| MNDR | hsa-miR-338-3p | Liver cancer | MNDR-E-MI-41298 |
| MNDR | hsa-miR-338-3p | Uterine cancer | MNDR-E-MI-41299 |
| MNDR | hsa-miR-338-3p | Cervical adenocarcinoma | MNDR-E-MI-41300 |
| MNDR | hsa-miR-338-3p | Lung squamous cell carcinoma | MNDR-E-MI-41301 |
| MNDR | hsa-miR-338-3p | Carcinoma lung non-small-cell | MNDR-E-MI-41302 |
| MNDR | hsa-miR-338-3p | Lung adenocarcinoma | MNDR-E-MI-41303 |
| MNDR | hsa-miR-338-3p | Thyroid carcinoma | MNDR-E-MI-41304 |
| MNDR | hsa-miR-338-3p | Bladder urothelial carcinoma | MNDR-E-MI-41305 |
| MNDR | hsa-miR-338-3p | Cervical cancer | MNDR-E-MI-41306 |
| MNDR | hsa-miR-338-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-41307 |
| MNDR | hsa-miR-338-3p | Carcinoma renal cell | MNDR-E-MI-41308 |
| MNDR | hsa-miR-338-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-41309 |
| MNDR | hsa-miR-338-3p | Renal clear cell carcinoma | MNDR-E-MI-41310 |
| MNDR | hsa-miR-338-3p | Large cell carcinoma | MNDR-E-MI-41311 |
| MNDR | hsa-miR-338-3p | Cholangiocarcinoma | MNDR-E-MI-41312 |
| MNDR | hsa-miR-338-3p | Esophageal cancer | MNDR-E-MI-41313 |
| MNDR | hsa-miR-338-3p | Lung small cell carcinoma | MNDR-E-MI-41314 |
| MNDR | hsa-miR-338-3p | Synovial sarcoma | MNDR-E-MI-41315 |
| MNDR | hsa-miR-338-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-41316 |
| MNDR | hsa-miR-338-3p | Fibromyalgia | MNDR-E-MI-41317 |
| MNDR | hsa-miR-338-3p | Adenoma | MNDR-E-MI-41318 |
| MNDR | hsa-miR-338-3p | Hepatocellular carcinoma | MNDR-E-MI-41319 |
| MNDR | hsa-miR-338-3p | B-cell lymphoma | MNDR-E-MI-41320 |
| MNDR | hsa-miR-338-3p | Rheumatoid arthritis | MNDR-E-MI-41321 |
| MNDR | hsa-miR-338-3p | Retinoblastoma | MNDR-E-MI-41322 |
| MNDR | hsa-miR-338-3p | Neuroblastoma | MNDR-E-MI-41323 |
| MNDR | hsa-miR-338-3p | Barrett's adenocarcinoma | MNDR-E-MI-41324 |
| MNDR | hsa-miR-338-3p | Hodgkin lymphoma | MNDR-E-MI-41325 |
| MNDR | hsa-miR-338-3p | Burkitt lymphoma | MNDR-E-MI-41326 |
| MNDR | hsa-miR-338-3p | Skin cutaneous melanoma | MNDR-E-MI-41327 |
| MNDR | hsa-miR-338-3p | Skin melanoma | MNDR-E-MI-41328 |
| MNDR | hsa-miR-338-3p | Acute myelocytic leukemia | MNDR-E-MI-41329 |
| MNDR | hsa-miR-338-3p | Colorectal cancer | MNDR-E-MI-41330 |
| MNDR | hsa-miR-338-3p | Hyperalgesia | MNDR-E-MI-41331 |
| MNDR | hsa-miR-338-3p | Prostatic neoplasms | MNDR-E-MI-41332 |
| MNDR | hsa-miR-338-3p | Peripheral nerve injuries | MNDR-E-MI-41333 |
| MNDR | hsa-miR-338-3p | Stroke lacunar | MNDR-E-MI-41334 |
| MNDR | hsa-miR-338-3p | Barrett's carcinogenesis | MNDR-E-MI-41335 |
| MNDR | hsa-miR-338-3p | Breast cancer her3+ negative | MNDR-E-MI-41336 |
| MNDR | hsa-miR-338-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-41337 |
| MNDR | hsa-miR-338-3p | Tubulovillous adenoma | MNDR-E-MI-41338 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAM17 | Homo sapiens | RR00040515 |
TOP